Stock comparison
Avantor, Inc. is 26.6x more valuable than EyePoint Pharmaceuticals, Inc. by market capitalization ($10.22 B vs $383.99 M). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
AVTR is larger
Avantor, Inc. is 26.6x more valuable than EyePoint Pharmaceuticals, Inc. by market capitalization ($10.22 B vs $383.99 M).
Market value leader
AVTR
Avantor, Inc. is 26.6x more valuable than EyePoint Pharmaceuticals, Inc. by market capitalization ($10.22 B vs $383.99 M).
Revenue leader
AVTR
EYPT: $31.37M vs AVTR: $6.55B.
Profit leader
EYPT
EYPT: -$231.96M vs AVTR: -$530.20M.
Margin leader
AVTR
EYPT: -739.4% vs AVTR: -8.1% net margin.
| Metric | EYPT | AVTR |
|---|---|---|
| Market cap | $383.99 M | $10.22 B |
| US-listed rank | #2673 | #943 |
| Revenue (latest FY) | $31.37M | $6.55B |
| Net income (latest FY) | -$231.96M | -$530.20M |
| Net margin | -739.4% | -8.1% |
| P/E (trailing FY) | - | - |
| SEC filings | 1,308 | 765 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
Avantor, Inc. is 26.6x more valuable than EyePoint Pharmaceuticals, Inc. by market capitalization ($10.22 B vs $383.99 M).
In their latest fiscal years, EyePoint Pharmaceuticals, Inc. reported $31.37M in revenue while Avantor, Inc. reported $6.55B.
Full pages: EyePoint Pharmaceuticals, Inc. and Avantor, Inc., or browse the full rankings.